A Population Pharmacokinetic Model-Guided Evaluation of Ceftolozane-Tazobactam Dosing in Critically Ill Patients Undergoing Continuous Venovenous Hemodiafiltration

被引:27
|
作者
Sime, Fekade B. [1 ,2 ]
Lassig-Smith, Melissa [3 ]
Starr, Therese [3 ]
Stuart, Janine [3 ]
Pandey, Saurabh [1 ]
Parker, Suzanne L. [1 ]
Wallis, Steven C. [1 ]
Lipman, Jeffrey [1 ,3 ,4 ]
Roberts, Jason A. [1 ,2 ,3 ,4 ,5 ]
机构
[1] Univ Queensland, Ctr Clin Res, Fac Med, Brisbane, Qld, Australia
[2] Univ Queensland, Ctr Translat Antiinfect Pharmacodynam, Sch Pharm, Brisbane, Qld, Australia
[3] Royal Brisbane & Womens Hosp, Dept Intens Care Med, Brisbane, Qld, Australia
[4] Univ Montpellier, Nimes Univ Hosp, Div Anaesthesiol Crit Care Emergency & Pain Med, Nimes, France
[5] Royal Brisbane & Womens Hosp, Pharm Dept, Brisbane, Qld, Australia
基金
英国医学研究理事会;
关键词
ceftolozane-tazobactam; pharmacokinetics; renal replacement therapy; hemodiafiltration; CRRT; RENAL REPLACEMENT THERAPY; PSEUDOMONAS-AERUGINOSA; CLEARANCE;
D O I
10.1128/AAC.01655-19
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The aim of this work was to describe optimized dosing regimens of ceftolozane-tazobactam for critically ill patients receiving continuous venovenous hemodiafiltration (CVVHDF). We conducted a prospective observational pharmacokinetic study in adult critically ill patients with clinical indications for ceftolozane-tazobactam and CVVHDF. Unbound drug concentrations were measured from serial prefilter blood, postfilter blood, and ultrafiltrate samples by a chromatographic assay. Population pharmacokinetic modeling and dosing simulations were performed using Pmetrics. A four-compartment pharmacokinetic model adequately described the data from six patients. The mean (+/- standard deviation [SD]) extraction ratios for ceftolozane and tazobactam were 0.76 +/- 0.08 and 0.73 +/- 0.1, respectively. The mean +/- SD sieving coefficients were 0.94 +/- 0.24 and 1.08 +/- 0.30, respectively. Model-estimated CVVHDF clearance rates were 2.7 +/- 0.8 and 3.0 +/- 0.6 liters/h, respectively. Residual non-CVVHDF clearance rates were 0.6 +/- 0.5 and 3.3 +/- 0.9 liters/h, respectively. In the initial 24 h, doses as low as 0.75 g every 8 h enabled cumulative fractional response of >= 85% for empirical coverage against Pseudomonas aeruginosa, considering a 40% fT (>MIC) (percentage of time the free drug concentration was above the MIC) target. For 100% fT (>MIC), doses of at least 1.5 g every 8 h were required. The median (interquartile range) steady-state trough ceftolozane concentrations for simulated regimens of 1.5 g and 3.0 g every 8 h were 28 (21 to 42) and 56 (42 to 84) mg/liter, respectively. The corresponding tazobactam concentrations were 6.1 (5.5 to 6.7) and 12.1 (11.0 to 13.4) mg/liter, respectively. We suggest a front-loaded regimen with a single 3.0-g loading dose followed by 0.75 g every 8 h for critically ill patients undergoing CVVHDF with study blood and dialysate flow rates.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] A PROSPECTIVE COMPARATIVE-STUDY OF CONTINUOUS ARTERIOVENOUS HEMODIAFILTRATION AND CONTINUOUS VENOVENOUS HEMODIAFILTRATION IN CRITICALLY ILL PATIENTS
    BELLOMO, R
    PARKIN, G
    LOVE, J
    BOYCE, N
    AMERICAN JOURNAL OF KIDNEY DISEASES, 1993, 21 (04) : 400 - 404
  • [22] Pharmacokinetics of Ertapenem in Critically Ill Patients Receiving Continuous Venovenous Hemodialysis or Hemodiafiltration
    Eyler, Rachel F.
    Vilay, A. Mary
    Nader, Ahmed M.
    Heung, Michael
    Pleva, Melissa
    Sowinski, Kevin M.
    DePestel, Daryl D.
    Soergel, Fritz
    Kinzig, Martina
    Mueller, Bruce A.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (03) : 1320 - 1326
  • [23] Optimal doses of caspofungin during continuous venovenous hemodiafiltration in critically ill patients
    Gerardo Aguilar
    Rafael Ferriols
    Angels Lozano
    Carlos Ezquer
    José A. Carbonell
    Ana Jurado
    Juan Carrizo
    Ferran Serralta
    Jaume Puig
    David Navarro
    Manuel Alos
    F. Javier Belda
    Critical Care, 21
  • [24] Optimal doses of caspofungin during continuous venovenous hemodiafiltration in critically ill patients
    Aguilar, Gerardo
    Ferriols, Rafael
    Lozano, Angels
    Ezquer, Carlos
    Carbonell, Jose A.
    Jurado, Ana
    Carrizo, Juan
    Serralta, Ferran
    Puig, Jaume
    Navarro, David
    Alos, Manuel
    Javier Belda, F.
    CRITICAL CARE, 2017, 21
  • [25] Pharmacokinetics of teicoplanin in critically ill patients undergoing continuous hemodiafiltration
    Yagasaki, K
    Gando, S
    Matsuda, N
    Kameue, T
    Ishitani, T
    Hirano, T
    Iseki, K
    INTENSIVE CARE MEDICINE, 2003, 29 (11) : 2094 - 2095
  • [26] Pharmacokinetics of teicoplanin in critically ill patients undergoing continuous hemodiafiltration
    Kazuaki Yagasaki
    Satoshi Gando
    Naoyuki Matsuda
    Takashi Kameue
    Toshiteru Ishitani
    Takeshi Hirano
    Ken Iseki
    Intensive Care Medicine, 2003, 29 : 2094 - 2095
  • [27] Doripenem population pharmacokinetics and dosing requirements for critically ill patients receiving continuous venovenous haemodiafiltration
    Roberts, Jason A.
    Udy, Andrew A.
    Bulitta, Juergen B.
    Stuart, Janine
    Jarrett, Paul
    Starr, Therese
    Lassig-Smith, Melissa
    Roberts, Natasha A.
    Dunlop, Rachel
    Hayashi, Yoshiro
    Wallis, Steven C.
    Lipman, Jeffrey
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2014, 69 (09) : 2508 - 2516
  • [28] Comparison of Sustained Hemodiafiltration With Continuous Venovenous Hemodiafiltration for the Treatment of Critically Ill Patients With Acute Kidney Injury
    Abe, Masanori
    Okada, Kazuyoshi
    Suzuki, Midori
    Nagura, Chinami
    Ishihara, Yuko
    Fujii, Yuki
    Ikeda, Kazuya
    Kaizu, Kazo
    Matsumoto, Koichi
    ARTIFICIAL ORGANS, 2010, 34 (04) : 331 - 338
  • [29] Treatment of multidrug-resistant Pseudomonas aeruginosa with ceftolozane/tazobactam in a critically ill patient receiving continuous venovenous haemodiafiltration
    Kuti, Joseph L.
    Ghazi, Islam M.
    Quintiliani, Richard, Jr.
    Shore, Eric
    Nicolau, David P.
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2016, 48 (03) : 342 - 343
  • [30] Measurement and calculation of the extracorporeal elimination of vancomycin during continuous venovenous hemodiafiltration and continuous venovenous hemofiltration in critically ill patients
    Muhl, E
    Bundesen, J
    Iven, H
    Bruch, HP
    JOURNAL OF INTENSIVE CARE MEDICINE, 2001, 16 (05) : 222 - 230